Safety profile of immune checkpoint inhibitors versus sorafenib as first-line treatment in advanced hepatocellular carcinoma: A meta-analysis of randomized controlled trials.

被引：0
|
作者：
Rizzo, Alessandro [1 ]
Frega, Giorgio [2 ]
Ricci, Angela Dalia [1 ]
Palloni, Andrea [1 ]
Tavolari, Simona [3 ]
Brandi, Giovanni [2 ]
机构：
[1] Univ Bologna, St Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy
[2] Policlin S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[3] Univ Bologna, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
315
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Outcomes of Immunotherapy Versus Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-Analysis of Randomized Clinical Trials
    Ponvilawan, Ben
    Sharma, Parth
    Mahadevia, Himil
    Subramanian, Janakiraman
    Bansal, Dhruv
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : E90 - E93
  • [32] Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials
    Zhang, Tao
    Ding, Xin
    Wei, Dong
    Cheng, Peng
    Su, Xiaomei
    Liu, Huanyi
    Wang, Daoyuan
    Gao, Hui
    ANTI-CANCER DRUGS, 2010, 21 (03) : 326 - 332
  • [33] PHARMACOECONOMIC EVALUATION OF SORAFENIB AS FIRST-LINE TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA
    Naumovska, Z.
    Nestorovska, Kapedanovska A.
    Grozdanova, A.
    Suturkova, L.
    Dimovski, A.
    Sterjev, Z.
    VALUE IN HEALTH, 2017, 20 (09) : A736 - A736
  • [34] Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials
    Tucci, Marcello
    Mandara, Marta
    Giuliani, Jacopo
    Durante, Emilia
    Buttigliero, Consuelo
    Turco, Fabio
    Palesandro, Erica
    Campisi, Ilaria
    Singh, Navdeep
    Muraro, Marco
    Munoz, Fernando
    Fiorica, Francesco
    CANCER TREATMENT REVIEWS, 2024, 127
  • [35] Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials
    Lu, Fenping
    Zhao, Kai
    Ye, Miaoqing
    Xing, Guangyan
    Liu, Bowen
    Li, Xiaobin
    Ran, Yun
    Wu, Fenfang
    Chen, Wei
    Hu, Shiping
    BMC CANCER, 2024, 24 (01)
  • [36] Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer: a meta-analysis of randomized controlled trials
    Bogani, Giorgio
    Monk, Bradley J.
    Barretina-Ginesta, Maria-Pilar
    Raspagliesi, Francesco
    Colombo, Nicoletta
    Slomovitz, Brian
    Mirza, Mansoor Raza
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A193 - A193
  • [37] Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis
    Monteiro, Fernando Sabino Marques
    Soares, Andrey
    Mollica, Veronica
    Leite, Caio Abner
    Carneiro, Andre Paterno Castello Dias
    Rizzo, Alessandro
    Bourlon, Maria T.
    Sasse, Andre Deeke
    Santoni, Matteo
    Gupta, Shilpa
    Massari, Francesco
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 196
  • [38] Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
    Manneh, Ray
    Lema, Mauricio
    Carril-Ajuria, Lucia
    Ibata, Linda
    Martinez, Susan
    Castellano, Daniel
    de Velasco, Guillermo
    BIOMEDICINES, 2022, 10 (03)
  • [39] Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
    Shu, Yamin
    Tang, Ying
    Ding, Yufeng
    Zhang, Qilin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122
  • [40] Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
    Zheng, Zhiwei
    Lin, Yuxuan
    Cai, Hongfu
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
12345